Peptrack™ Peptide Libraries

JPT Peptide Technologies is the leading provider of peptide libraries for T-cell assays and proteomic applications worldwide. Together with its partners in the vaccine industry, governmental and non-profit organizations, as well as universities JPT defined specific requirements for peptides to be used for T-cell assays in the various phases of vaccine development. These specifications were translated to a product line called PepTrack™ Peptide Libraries offering tailor made solutions for all peptide needs in vaccine development. Using its regulated environment (DIN EN ISO 9001:2008, GCLP), JPT produces more individual peptides on an annual basis than any other company worldwide.

Available PepTrack™ Options:

All PepTrack™ Levels are optimized towards performance in T-cell assays

Fast Track - Peptrack™ Peptide Libraries

Synthesized by JPT’s proprietary synthesis method Fast Track Peptide Libraries represent the most inexpensive source of peptides worldwide. The ability to produce tens-of-thousands of peptides within weeks offers T-cell epitope discovery, biological screening and identification of proteotypic peptides at proteome-wide levels

* additional QC available upon request
Delivery Format: 96-well plate format

Research Track - Peptrack™ Peptide Libraries

Research Track Peptide Libraries are designed for applications in T-cell assays requiring large numbers of fully analyzed peptides in quantities of 1-5mg. All peptides are fully analyzed for identity and purity by LC-MS (no MALDI-MS!). In addition, JPT’s peptide synthesis protocols are optimized to avoid contaminations and failure sequences which cause either false positive T-cell responses or toxic inhibition

* for larger amounts please inquire
Delivery Format: 96-array tube format

Discovery Track - Peptrack™ Peptide Libraries

Discovery Track Peptide Libraries have defined purities for applications requiring similar and specified purities of all peptides (i.e. immune monitoring). Each peptide has a guaranteed minimum specification. All peptides will be QC’d by LC-MS (not MALDI-MS!).

*for larger amounts please inquire
Delivery Format: 96-array tube format

Trial Track - Peptrack™ Peptide Libraries

Trial Track Peptide Libraries were designed to provide a reliable source of peptides and peptide pools for application as monitoring tools in clinical vaccination trials. All productions run in a regulated environment according to DIN EN ISO 9001:2008 & Good Clinical Laboratory Practices (GCLP) regulations. Synthesis protocols were optimized to reduce toxic contaminations as well as formation of deletion peptides and cross contaminants causing false positive T-cell responses. All peptides have guaranteed purities.

* full analytical coverage including amino acids analysis, capillary electrophoresis, peptide content determination, determination of residual solvents etc. is available upon request ** for larger amounts please inquire Delivery Format: 96-array tube format

Benefits of Peptrack™ Peptide Libraries:

• Selection of different peptide specifications tailored for cell based assay applications
• Best pricing in industry starts at 7 $/€ per peptide
• Whole production performed in a regulated European environment according to DIN EN ISO 9001:2008 & GCLP standards; audits welcome!
• Synthesis protocols designed to avoid toxic contaminants and side products causing false positive T-cell responses
• Special synthesis technology inhibits side products causing false positive T-cell responses
• Provision of freeze dried aliquots for enhanced stability, validated pooling & vialing available
• Proven track record for applications in clinical studies

Applications for Peptrack™ Peptide Libraries:

• T-cell epitope discovery
• Peptide vaccine development
• T-cell epitope mapping and validation
• Immune monitoring
• Optimization and validation of T-cell assays
• Vaccine efficacy testing
• Cell therapy approaches
• Biological screening Identification of proteotypic peptides

Please inquire about additional services not listed here.

Testimonials for Peptrack™ Peptide Libraries

"I have been collaborating with JPT for several years. Their unique peptide library technologies and knowledge of specific peptide requirements for T-cell assays made them a valuable, long-term partner in our efforts to develop novel adoptive immunotherapy approaches to prevent and treat viral infections post-transplant as well as for the treatment of virus and non virus-associated malignancies. Furthermore, their reagents allow us to precisely monitor and track specific T cell populations post-infusion"
Ann Leen, PhD (Baylor College of Medicine, Center for Cell and Gene Therapy, Houston, TX, USA)

“We utilize JPT’s peptide libraries and pools for T-cell epitope mapping and immune monitoring applications such as ELISPOT and ICS, as well as CFC. The combination of synthesis economy, quick turnaround time and tailored specifications are key to our success. JPT’s scientific competence is invaluable for all institutions planning to employ peptides in immuno assays for research or clinical setups."
Johannes Hampl, PhD (Anza Therapeutics, Inc Concord, CA, USA)

References for Peptrack™ Peptide Libraries:

The NK Cell Response to Mouse Cytomegalovirus Infection Affects the Level and Kinetics of the Early CD8+ T-Cell Response
Mitrovic et al., J. Virol. (2012)
A New Antigen Scanning Strategy for Monitoring HIV-1 Specific T-cell Immune Responses
Manati et al. Journal of Immunological Methods (2012)
Structural Basis and Sequence Rules for Substrate Recognition by Tankyrase Explain the Basis for Cherubism Disease
Guettler et al., j.cell (2011)
Immune Responses to Transgene and Retroviral Vector in Patients Treated with Ex Vivo -Engineered T Cells
Lamers et al., Blood (2011)
Integrated NY-ESO-1 Antibody and CD8+ T-cell Responses Correlate with Clinical Benefit in Advanced Melanoma Patients Treated with Ipilimumab
Yuan et al., PNAS (2011)
Strong Human Endogenous Retrovirus-Specific T Cell Responses Are Associated with Control of HIV-1 in Chronic Infection
SenGupta et al., J. Virol. (2011)
Telomerase and HER-2/neu as Targets of Genetic Cancer Vaccines in Dogs
Peruzzi et al, Vaccine 28 (2010)
Functional Characterization of Aquaporin-4 Specific T Cells: Towards a Model for Neuromyelitis Optica
Reddy kalluri et. al., PLoS ONE (2011)
Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate
Currier et. al., PLoS ONE (2010)

More references under JPT Publications/Literature